Sep 18, 2025

commercial debut of BioMetaControl™, its first bioactive ingredient targeted for metabolic health. This launch marks Brightseed's expansion beyond digestive wellness into the growing field of blood glucose management and metabolic support. BioMetaControl is a pivotal milestone for Brightseed as we expand into metabolic health, building on our foundation in digestive wellness and further proving Forager's discovery capabilities. A Breakthrough in Metabolic Health: NCT and NFT Blood glucose regulation is central to overall metabolic health. HNF4-alpha is a 'master metabolic switch' that plays a pivotal role in blood glucose regulation. Brightseed's proprietary AI platform, Forager® , successfully identified bioactives, n-trans-Caffeoyl Tyramine ( NCT ) and n-trans-Feruloyl Tyramine ( NFT ), as potent HNF4-alpha agonists. By activating HNF4α, bioactives in BioMetaControl have been shown to address three key consumer and GLP-1 user needs supported in a forthcoming peer-reviewed human clinical study Bioactives NCT & NFT: Clinically Proven Benefits for Blood Glucose Control, Energy (subject testimonials), and Digestive Relief In a recent randomized, double-blind, parallel-arm, clinical study (n=126), NCT and NFT administered as BioMetaControl demonstrated a statistically significant improvement in fasting blood glucose, fasting insulin, and post-meal glucose levels in prediabetic subjects. BioMetaControl was found to improve these parameters in just 30 days. These improvements were not only found in outcomes that represent a snapshot in time, such as fasting blood glucose, fasting insulin levels, and post-meal blood glucose levels, but also in measures of continuous glucose monitoring over a period of 24 hours. The study results have been submitted to a peer-reviewed journal and are expected to be published in Q4 2025. In a separate, peer-reviewed and published study*, NCT and NFT at the same dose presented with digestive relief benefits emerging in under three weeks. At a low daily dose of 120mg, BioMetaControl offers a high-impact, sustained-release solution that is easy to formulate into capsules, tablets, soft gels, or functional beverages. Brightseed's Forager® AI: From Discovery to Scale Following the recent launch of Bio Gut Core , Brightseed's clinically proven gut health ingredient, BioMetaControl is the latest example of Brightseed's end-to-end capabilities: discovery through Forager AI, clinical validation, and production at scale. This launch demonstrates Brightseed's ability to deliver proprietary bioactives from nature to market-ready ingredients, setting a new standard for precision bioactives in human health. “BioMetaControl is a pivotal milestone for Brightseed as we expand into metabolic health, building on our foundation in digestive wellness and further proving Forager's discovery capabilities,” said Lee Chae, Co-Founder and CEO, Brightseed. “We are excited to provide brands with a clinically proven, nature-powered solution that supports blood glucose control and complements the use of GLP-1 therapies.” For more information about BioMetaControl and partnership opportunities, please visit https://www.brightseedbio.com/bio-meta-control/ *DOI: https://doi.org/10.31989/bchd.v8i6.1655 About Brightseed Brightseed® , the bioactives leader unlocking nature with AI to elevate human health, is a World Economic Global Innovator. Brightseed's proprietary AI, Forager®, accelerates bioactive discovery, biological validation, and ingredient formulation from years to months, rapidly revealing new connections between nature and humanity. Brightseed produces clinically-proven bioactives for dietary supplements, food & beverage CPG, specialty nutrition, and medical foods to power proactive health worldwide. Learn more at brightseedbio.com